New Hope in a Capsule: Actinogen’s Oral Alzheimer’s Remedy Enters Pivotal Trial Section
A promising new oral remedy for Alzheimer’s illness is now recruiting contributors throughout the USA, providing recent hope to households affected by this devastating situation. Actinogen Medical’s XanaMIA Section 2b/3 trial is testing the efficacy of Xanamem®, a once-daily capsule designed to sluggish cognitive decline by focusing on cortisol—the mind’s stress hormone.
What Is Xanamem?
Xanamem® (emestedastat) is a first-in-class oral drug that inhibits the enzyme 11β-HSD1, which regulates cortisol manufacturing within the mind. Elevated cortisol is linked to reminiscence loss and cognitive decline in Alzheimer’s illness. By decreasing cortisol in key mind areas just like the hippocampus, Xanamem goals to protect cognitive perform with out disrupting the physique’s regular hormone steadiness.
Concerning the XanaMIA Trial
- Design: Randomized, double-blind, placebo-controlled
- Remedy Interval: 36 weeks, adopted by a 24-month open-label extension
- Contributors: 220 people with gentle to average Alzheimer’s
- Major Endpoint: Medical Dementia Ranking – Sum of Bins (CDR-SB)
- Trial Websites: 20 areas throughout the U.S.
The trial is designed to be low-burden—no lumbar punctures or frequent mind scans. Contributors take a each day capsule and attend common clinic visits for cognitive assessments.
Who Can Be part of?
Eligible contributors should:
- Be 50 years or older
- Have a analysis of gentle to average Alzheimer’s
- Have a examine companion who can attend clinic visits
- Not have obtained anti-amyloid antibody remedy up to now 6 months
Among the many 30 Trial Areas
- California: Carlsbad, Orange, Sherman Oaks
- Colorado: Denver, Englewood
- Florida: Delray Seashore, Miami, New Port Richey, Orlando, The Villages
- Georgia: Decatur
- New Jersey: Toms River
- New York: Albany, Staten Island
- Ohio: Dayton, Independence
- Oregon: Portland
- Rhode Island: East Windfall
- Texas: Austin
- Washington: Bellevue
What’s Subsequent?
Actinogen has enrolled over 100 contributors and plans an interim evaluation in January 2026, with remaining outcomes anticipated by late 2026. If profitable, Xanamem might develop into a game-changing oral remedy—both as a standalone therapy or together with present medication like Leqembi.
Why It Issues
Not like anti-amyloid therapies that require infusions and carry dangers of mind swelling, Xanamem presents a easy, oral various with a powerful security profile. It’s been studied in over 400 folks throughout eight trials and has proven potential advantages for each Alzheimer’s and melancholy.
For households in search of a much less invasive, extra accessible therapy, this trial might mark a turning level.
Methods to Be taught Extra
You could find out extra in regards to the XanaMIA trial within the following methods:
Verify eligibility on-line
E-mail Actinogen’s medical trials group: clinicaltrials@actinogen.com.au
Go to the XanaMIA trial web site
The publish Xanamem for Alzheimer’s Trial: A Single Capsule As soon as a Day appeared first on Alzheimer's And Dementia Weekly.